Differential <sup>18</sup>F-FDG and <sup>18</sup>F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non–Small Cell Lung Cancer

Everitt, Sarah; Ball, David; Hicks, Rodney J.; Callahan, Jason; Plumridge, Nikki; Collins, Marnie; Herschtal, Alan; Binns, David; Kron, Tomas; Schneider-Kolsky, Michal Elisabeth; MacManus, Michael

doi:10.2967/jnumed.113.131631

Cited by 74 publications

(91 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To overcome this limitation, exploratory studies of interim tumor response monitoring have focused on other hallmarks of cancer, including rapid cellular proliferation (e.g., FLT) and hypoxia (e.g., FMISO). The ability of FLT to detect an early proliferative response in NSCLC was reported by Everitt and colleagues who performed both FDG and FLT PET/CT scans during the second and fourth weeks of CRT in 60 patients ( Figure 4A) (78). Recent findings of this study revealed that patients with tumors displaying stable disease (SD) on week two FLT PET/CT scans experienced significantly longer progression free and overall survival than patients with tumors that displayed a partial or complete reduction in FLT uptake (27).…”

Section: Response Assessment With Pet During Rtmentioning

confidence: 55%

Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization

MacManus

Everitt

Schimek-Jasch

et al. 2017

Transl. Lung Cancer Res.

Self Cite

View full text Add to dashboard Cite

This article reviews key imaging modalities for lung cancer patients treated with radiation therapy (RT) and considers their actual or potential contributions to critical decision-making. An international group of researchers with expertise in imaging in lung cancer patients treated with RT considered the relevant literature on modalities, including computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). These perspectives were coordinated to summarize the current status of imaging in lung cancer and flag developments with future implications.Although there are no useful randomized trials of different imaging modalities in lung cancer, multiple prospective studies indicate that management decisions are frequently impacted by the use of complementary imaging modalities, leading both to more appropriate treatments and better outcomes. This is especially true of 18 F-fluoro-deoxyglucose (FDG)-PET/CT which is widely accepted to be the standard imaging modality for staging of lung cancer patients, for selection for potentially curative RT and for treatment planning. PET is also more accurate than CT for predicting survival after RT. PET imaging during RT is also correlated with survival and makes response-adapted therapies possible. PET tracers other than FDG have potential for imaging important biological process in tumors, including hypoxia and proliferation. MRI has superior accuracy in soft tissue imaging and the MRI Linac is a rapidly developing technology with great potential for online monitoring and modification of treatment. The role of imaging in RT-treated lung cancer patients is evolving rapidly and will allow increasing personalization of therapy according to the biology of both the tumor and dose limiting normal tissues.

show abstract

Section: Response Assessment With Pet During Rtmentioning

confidence: 55%

Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization

MacManus

Everitt

Schimek-Jasch

et al. 2017

Transl. Lung Cancer Res.

Self Cite

View full text Add to dashboard Cite

show abstract

“…18 F-FLT has since been used to assess treatment response in breast cancer [164] and lymphoma [165,166], among others. Clinical reports also show that 18 F-FLT is a more reliable and sensitive tracer for evaluating treatment response than 18 F-FDG [167][168][169]. However, further clinical evaluation is needed to validate the utility of 18 F-FLT-PET.…”

Section: Imaging Of Tumor Cell Proliferation During Treatmentmentioning

confidence: 92%

Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies

Spence

Souza

Dou

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

“…However, the presence of inflammatory abnormalities may reduce the specificity. In such a context, 18 F-FLT PET/CT has proved to be a more sensitivity for early treatment response evaluation [40]. Although it is currently unclear whether these changes predict the eventual clinical outcome, its potential utility to clarify recurrent disease when it is strongly suspected can be considered.…”

Section: Future Perspectivesmentioning

confidence: 99%

The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer

et al. 2016

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide and its prognosis remains poor. Molecular imaging with 18F-FDG PET/CT can metabolically characterize the nature of lesions as benign or malignant, allowing a better staging at the diagnosis of this kind of patient. This advantage can also be applied in the re-staging due to the suspicion of recurrent disease. Many patients have a recurrence of the disease, including surgically treated patients. In the current context, with new personalized oncological treatments, the surveillance for recurrence and its accurate diagnosis are crucial to improve their survival. In this paper, we revise the current knowledge about the clinical and molecular factors related to the recurrent disease. In the context of new, promising, available personalized treatments, the role of molecular imaging with PET/CT and 18F-FDG and non-18F-FDG radiotracers in the follow-up of NSCLC-treated patients is especially attractive and interesting.

show abstract

Differential ¹⁸F-FDG and ¹⁸F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non–Small Cell Lung Cancer

Cited by 74 publications

References 19 publications

Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization

Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization

Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies

The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About

Differential 18F-FDG and 18F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non–Small Cell Lung Cancer

Cited by 74 publications

References 19 publications

Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization

Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization

Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies

The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About

Differential ¹⁸F-FDG and ¹⁸F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non–Small Cell Lung Cancer